Patents by Inventor Joseph Negri

Joseph Negri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130338092
    Abstract: This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.
    Type: Application
    Filed: August 16, 2013
    Publication date: December 19, 2013
    Inventors: Kimberly Hartwell, Malcolm A.S. Moore, David T. Scadden, Stuart L. Schreiber, Todd R. Golub, Benito Munoz, Benjamin L. Ebert, Andrew M. Stern, Peter G. Miller, D. Gary Gilliland, Anne Van Dyk Carpenter, David J. Logan, Joseph Negri, Nicola Tolliday, Alykhan Shamji, Siddhartha Mukherjee, Alison Stewart
  • Patent number: 8466147
    Abstract: Herein is provided methods and compositions for treating cancer. In one embodiment, a method is provided for treating a patient suffering from cancer, the method comprising administering to the patient an effective amount of reversine, reversine analog or reversine containing agent. In another embodiment, compositions comprising reversine are provided. Such compositions may further comprise additional active agents and other additives. The compositions and methods provided herein are useful, for example, in the area of medicine.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: June 18, 2013
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, Nicholas Mitsiades, Joseph Negri, Douglas W. McMillin, Constantine S. Mitsiades
  • Publication number: 20100286090
    Abstract: Methods for treating multiple myeloma comprising administering a therapeutically effective amount of dasatinib to a patient in need of treatment thereof. Dasatinib can be administered alone or in combination with a second anti-neoplastic agent such as dexamethasone or bortezomib. The patient may be refractory to prior treatment with an anti-neoplastic agent other than dasatinib.
    Type: Application
    Filed: November 14, 2006
    Publication date: November 11, 2010
    Inventors: Constantine S Mitsiades, Qingwei Deng, Nicholas S. Mitsiades, Kenneth C. Anderson, Joseph Negri
  • Publication number: 20100172893
    Abstract: Herein is provided methods and compositions for treating cancer. In one embodiment, a method is provided for treating a patient suffering from cancer, the method comprising administering to the patient an effective amount of reversine, reversine analog or reversine containing agent. In another embodiment, compositions comprising reversine are provided. Such compositions may further comprise additional active agents and other additives. The compositions and methods provided herein are useful, for example, in the area of medicine.
    Type: Application
    Filed: November 12, 2007
    Publication date: July 8, 2010
    Inventors: Kenneth C. Anderson, Nicholas Mitsiades, Joseph Negri, Douglas W. McMillin, Constantine S. Siades
  • Patent number: 6090635
    Abstract: A heterostructure device includes a ridge-waveguide laser monolithically integrated with a ridge-waveguide rear facet monitor (RFM). An integral V-groove etched directly into the device substrate enables passive alignment of an optical fiber to the active region of the laser. The layer and RFM facets were formed using an in-situ multistep reactive ion etch process.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: July 18, 2000
    Assignee: GTE Laboratories Incorporated
    Inventors: Mark Alan Rothman, Chan-Long Shieh, Craig Alfred Armiento, John Alvin Thompson, Alfred Joseph Negri